# Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

> **NCT05806047** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 23 (estimated)

## Conditions studied

- Hormone Receptor-positive Advanced Breast Cancer

## Interventions

- **DRUG:** chidamide combined with fulvestrant

## Key facts

- **NCT ID:** NCT05806047
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806047, "Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05806047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*